Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere Acquires China Rights to Novel Stroke Drug from Canadian Biotech

publication date: May 12, 2020

Nanjing's Simcere Pharma has acquired greater China rights to a novel product aimed at treating stroke from Canada's Primary Peptides. In 2014, Primary Peptides was spun out of the University of British Columbia to develop drugs based on preventing protein toxic cascades that kill brain cells due to trauma, stroke or disease. It out-licensed its first product to Yabao Pharma of Beijing in a $40 million agreement. Simcere will have rights to the candidate in mainland China, Hong Kong, Macau and Taiwan. Financial terms were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here